Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03976115
Other study ID # DDO-3055-101
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 18, 2019
Est. completion date May 11, 2021

Study information

Verified date June 2022
Source Jiangsu HengRui Medicine Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, dose-escalating, placebo controlled, Phase I study to evaluate the safety, pharmacokinetics and pharmacodynamics of DDO-3055 in healthy volunteers and patients with chronic kidney disease. 48 healthy volunteers will be enrolled in Part A, and 18 patients with chronic kidney disease will be enrolled in Part B.


Recruitment information / eligibility

Status Completed
Enrollment 54
Est. completion date May 11, 2021
Est. primary completion date May 11, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Healthy volunteers: Male or female volunteers aged 18 to 45 years of age inclusive ; Hemoglobin is 120 to 160 g/L; In good health, at the discretion of the investigator, as determined by: medical history, physical examination, vital sign assessment, 12-lead ECG, clinical laboratory evaluations. - Patients with chronic kidney disease : Male or female patients with chronic kidney disease who are 18 to 45 years of age inclusive; Hemoglobin is =100 g/L; 30mL/min/1.73m2 = eGFR = 60mL/min/1.73m2(according to CKD-EPI formula); - Body weight is = 50kg, and 19kg/m2 = body mass index<26kg/m2 . - Normal iron reserves (serum iron >61 g/dL and serum ferritin normal >30ng/mL). - Signed informed consent. Exclusion Criteria: Healthy volunteers: - The serum creatinine exceeded the upper limit of normal value in the screening period. Healthy volunteers and patients with chronic kidney disease: - Allergic to the study drug or any of its ingredients. - Treating or treated with erythropoiesis stimulating agents for 1 month before screening. - Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or gamma-glutamyl transferase (GGT) or total bilirubin above 1.5 times normal upper limit (ULN) in the screening period. - Have a history of blood donation or blood transfusion within 3 months. - Vein blood collection is difficult or physical condition can not afford blood collection. - Hepatitis b surface antigen (HBsAg), hepatitis c antibody (HCVAb), syphilis antibody, or human immunodeficiency virus (HIV) antibody test is positive in the screening period. - Smoking 5 cigarettes per day on average within 3 months; or the average daily intake of alcohol within one week is more than 15g (15g alcohol is equivalent to 450mL beer or 150mL wine or 50mL low-alcohol liquor) or 2 days before taking the study drug and during the study period, tobacco, alcohol and caffeinated food or beverage are not prohibited, or those with special dietary requirements cannot comply with the unified diet. - Those who have participated in clinical trials of any drug or medical device within 3 months prior to screening, or those who have participated in the drug trial within 5 half-lives prior to screening; any health product (within 1 week prior to administration), over-the-counter drug (2 weeks prior to administration) or prescription drug (1 month prior to administration) that affects the absorption, distribution, metabolism or excretion of the tested drug. - With a history of drug abuse or positive screening/baseline test for substance abuse and drug urinalysis. - During the study period and within 30 days after administration, men who are unwilling to take contraceptive measures and promise not to donate sperm are not allowed to participate in the study. Childbearing women who did not use contraception at least 14 days before administration; men and women who did not agree to use physical contraception during the study period. - Women with serum HCG = 5 mIU/mL or nursing in the screening period or baseline - Any physical or mental illness or condition that may increase the risk of the study, affect the subject's compliance with the protocol, or affect the subject's ability to complete the study, as determined by the study physician.

Study Design


Intervention

Drug:
DDO-3055
Oral
Placebos
Oral

Locations

Country Name City State
China Guangdong Provincial People's Hospital Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Events(AEs) and Serious Adverse Events (SAEs) Incidence of AEs and SAEs, incidence of Treatment-Emergent Adverse Events from informed consent form signature to the end of the study (up to 14 days)
Secondary Area under the plasma concentration versus time curve (AUC) of DDO-3055 Pre-dose to 72 hours after dose administration
Secondary Maximum observed serum concentration (Cmax) of DDO-3055 Pre-dose to 72 hours after dose administration
Secondary Time to maximum observed serum concentration (tmax) of DDO-3055 Pre-dose to 72 hours after dose administration
Secondary Time to elimination half-life (t1/2) of DDO-3055 Pre-dose to 72 hours after dose administration
Secondary Apparent total clearance of the drug from plasma after oral administration (CL/F) of DDO-3055 Pre-dose to 72 hours after dose administration
Secondary Apparent volume of distribution after non-intravenous administration (V/F) of DDO-3055 Pre-dose to 72 hours after dose administration
Secondary Renal clearance of the drug from plasma (CLR) of DDO-3055 Pre-dose to 72 hours after dose administration
Secondary Changes in red blood cell count relative to baseline up to 14 days
Secondary Changes in reticulocyte count relative to baseline up to 14 days
Secondary Changes in hemoglobin relative to baseline up to 14 days
Secondary Changes in endogenous erythropoietin relative to baseline up to 14 days
See also
  Status Clinical Trial Phase
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Terminated NCT04043026 - The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
Completed NCT05318014 - Low-protein Formula Supplements in Chronic Kidney Disease N/A
Active, not recruiting NCT06071065 - Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients N/A
Completed NCT02878317 - Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
Not yet recruiting NCT06039254 - Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function Phase 1
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease
Completed NCT02836574 - A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease Phase 2
Completed NCT02875886 - DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease Phase 4
Completed NCT02896309 - The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity N/A
Withdrawn NCT02885545 - The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial Phase 4
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT02756520 - Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
Active, not recruiting NCT02483039 - Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization N/A
Completed NCT02992548 - Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Phase 4
Terminated NCT02543177 - Optimised Procedure in Patients With NSTEMI and CKD N/A
Completed NCT02369549 - Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease Phase 3
Recruiting NCT02205944 - Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes N/A
Active, not recruiting NCT02231138 - Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Phase 4